Study to determine the safety and effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers.
Each subject will be given an Ariva® Silver Wintergreen lozenge or a Silver Wintergreen lozenge, which contains only silver salt, on a random basis. Once the lozenge has dissolved in the mouth, subjects will smoke one of their own cigarettes, and will answer questions about the experience and their craving for a cigarette. After a washout period, each subject will repeat the steps with the second type of lozenge.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
111
Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
Comfort Inn
Martinsburg, West Virginia, United States
Effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers
Effectiveness to be measured by the change in score on a craving questionnaire, from before to after product use.
Time frame: 90 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.